Updates & Blogs


Featured Story

Researchers Announce the VHFC 3Fever™ RDT

Performance data on a newly developed prototype multi-agent lateral flow immunoassay (LFI) for the detection and differentiation of malaria, Lassa fever and Ebola fever was presented by VHFC members at the recent American Society of Tropical Medicine and Hygiene conference in Philadelphia. The 3Fever™ test uses VHFC reagents which are considered to be the best in the world for this purpose. Initial clinical and analytical studies of the 3Fever™ test demonstrated excellent performance and the test will continue to be further advanced towards regulatory approvals and commercialization by Tulane, Autoimmune Technologies, Zalgen Labs and other VHFC partners. View poster

PSD to Drupal theme